Protagonist Lands FDA Win, Threatens Immunology Giants
Protagonist’s First Approval Spells Trouble for Pharma’s Immunology Heavyweights
Biotech, Pharmaceutical and Clinical Research Jobs | BioSpace2026.03.18Updated 27d ago
Protagonist Therapeutics will now sit back and collect cash from the J&J partnership, including an immediate $50 million payment.
AI SummaryPowered by AI
Protagonist Therapeutics received its first FDA approval, securing a $50 million immediate payment from its Johnson & Johnson partnership. The breakthrough positions the biotech company to challenge established players in the immunology sector. Industry analysts suggest the approval could reshape competitive dynamics among major pharmaceutical immunology programs.
protagonist therapeuticsfda approvaljohnson & johnsonimmunologybiotech partnershippharmaceuticalprotagonistsfirstapprovalspells
Explore More
Related News
NASA to Host Artemis II Crew Postflight News Conference - NASA
NASA · 2026.04.14
US eyes potential second round of in-person talks with Iran as blockade takes hold | CNN Politics
CNN · 2026.04.14
Embattled GOP Rep. Tony Gonzales announces he’s stepping down from Congress | CNN Politics
CNN · 2026.04.14
JD Vance had a vision for the world. Trump is wrecking it.
Vox · 2026.04.14
US intel officials scramble to keep surveillance law running amid Iran war tensions | CNN Politics
CNN · 2026.04.14
Judges fired after blocking deportation of pro-Palestinian students
The Guardian · 2026.04.14